Patents by Inventor Lars Klareskog

Lars Klareskog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Citrullinated peptides that bind to types of MHC class II and their use on diagnosis and treatment
    Patent number: 12180265
    Abstract: A pharmaceutical composition comprises (a) a peptide of 8 to 20 amino acids comprising at least one citrulline residue and 13, 14 or 15 consecutive amino acids residues with a sequence present in SEQ ID NO 22 or a complex of said peptide and a human recombinant MHC class II protein, and (b) an immunologic adjuvant.
    Type: Grant
    Filed: May 20, 2020
    Date of Patent: December 31, 2024
    Assignee: Curara AB
    Inventors: Lars Klareskog, Vivianne Malmstström
  • SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
    Publication number: 20240010703
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Application
    Filed: August 22, 2023
    Publication date: January 11, 2024
    Applicants: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James MATTHAEI, Anne-Renee VAN DER VUURST DE VRIES, Joshua BEILKE, Vivianne MALMSTRÖM, Kathryn HOOPER, Rebecca JOHNSON, Lars KLARESKOG
  • Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory T cells to treat autoimmune diseases
    Patent number: 11753457
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Grant
    Filed: November 22, 2022
    Date of Patent: September 12, 2023
    Assignees: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James Matthaei, Anne-Renee van der Vuurst de Vries, Joshua Beilke, Vivianne Malmström, Kathryn Hooper, Rebecca Johnson, Lars Klareskog
  • SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
    Publication number: 20230080155
    Abstract: Disclosed herein are chimeric antigen receptors (“CARs”) comprising an antigen binding site that recognizes citrullinated polypeptides. Citrullinated polypeptides, such as citrullinated vimentin, fibrinogen, and filaggrin, are expressed in the synovium of subjects with rheumatoid arthritis. Further disclosed are T cells, and in particular, Treg cells, that express these CARs. Administration of these CAR-T cells is useful in the treatment of rheumatoid arthritis as well as other diseases associated with citrullinated peptides.
    Type: Application
    Filed: November 22, 2022
    Publication date: March 16, 2023
    Applicants: Sonoma Biotherapeutics, Inc., Curara AB
    Inventors: James MATTHAEI, Anne-Renee Van Der Vuurst De Vries, Joshua Beilke, Vivianne Malmstrom, Kathryn Hooper, Rebecca Johnson, Lars Klareskog
  • Inhibition of IL-8 in the treatment of pain and/or bone loss
    Patent number: 10940126
    Abstract: Pain associated with a contribution of IL-8 and osteoclasts in a subject is prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting or blocking the action of interleukin 8 (IL-8). Methods and compounds for this use are disclosed, as well as a diagnostic method and kit.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 9, 2021
    Inventors: Camilla Svensson, Lars Klareskog, Vivianne Malmstrom, Anca Catrina
  • NOVEL PEPTIDES THAT BIND TO TYPES OF MHC CLASS II AND THEIR USE ON DIAGNOSIS AND TREATMENT
    Publication number: 20200277357
    Abstract: A pharmaceutical composition comprises (a) a peptide of between 8 and 20 amino acids comprising at least 8 consecutive amino acids residues with a sequence present in SEQ ID NO 22 or a complex of said peptide and a human recombinant MHC class II protein and (b) an immunologic adjuvant.
    Type: Application
    Filed: May 20, 2020
    Publication date: September 3, 2020
    Inventors: Lars Klareskog, Vivianne Malmstström
  • INHIBITION OF IL-8 IN THE TREATMENT OF PAIN AND/OR BONE LOSS
    Publication number: 20170181987
    Abstract: Pain associated with a contribution of IL-8 and osteoclasts in a subject is prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting or blocking the action of interleukin 8 (IL-8). Methods and compounds for this use are disclosed, as well as a diagnostic method and kit.
    Type: Application
    Filed: December 29, 2016
    Publication date: June 29, 2017
    Inventors: Camilla SVENSSON, Lars KLARESKOG, Vivianne MALMSTROM, Anca CATRINA
  • METHODS AND COMPOUNDS FOR THE TREATMENT OF BONE LOSS AND/OR PAIN
    Publication number: 20170105971
    Abstract: Bone loss and/or pain associated with an elevated activation of osteoclasts is prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting the activity of a peptidylarginine deiminase (PAD) enzyme. Methods and compounds for this use are disclosed, as well as diagnostic methods, kits, and a method for identifying compounds effective to prevent, treat and/or alleviate bone loss and/or pain.
    Type: Application
    Filed: December 29, 2016
    Publication date: April 20, 2017
    Inventors: Anca CATRINA, Camilla SVENSSON, Lars KLARESKOG, Vivianne MALMSTROM
  • Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
    Publication number: 20160159922
    Abstract: Novel antibodies or binding fragments thereof, which exhibit specific binding to citrullinated epitopes are disclosed, as well as pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in diagnosis, in prognostics, treatment and/or alleviation of rheumatoid arthritis, as well as processes for generating and preparing said antibodies.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 9, 2016
    Inventors: Lars KLARESKOG, Vivianne MALMSTRÖM, Johanna Maria ÅKERBLÖM STEEN, Daniel John LIGHTWOOD, Stephen Edward RAPECKI
  • NOVEL PEPTIDES THAT BIND TO TYPES OF MHC CLASS II AND THEIR USE ON DIAGNOSIS AND TREATMENT
    Publication number: 20150218546
    Abstract: It is provided novel peptides from human alpha-enolase, collagen type II and vimentin that bind to types of MHC class II that is associated with rheumatoid arthritis. There is also provided novel therapies and methods for diagnosis of rheumatoid arthritis.
    Type: Application
    Filed: April 5, 2012
    Publication date: August 6, 2015
    Inventors: Lars Klareskog, Vivianne Malmstström, Rikard Holmdahl
  • NOVEL ANTIBODIES
    Publication number: 20150056208
    Abstract: Autoimmune reactions to certain epitopes of self antigens most likely contribute to the development of rheumatoid arthritis. Often these epitopes are citrullinated. The present invention relates generally to novel antibodies that can bind to certain citrullinated epitopes namely citrullinated enolase, vimentin, fibrinogen and citrullinated synthetic peptides. These antibodies can be used in diagnostics of rheumatoid arthritis, for therapy against rheumatoid arthritis and as research tools.
    Type: Application
    Filed: July 17, 2014
    Publication date: February 26, 2015
    Applicant: VILARA AB
    Inventors: Lars Klareskog, Vivianne Malmström, Khaled Amara
  • Treatment of rheumatoid arthritis
    Publication number: 20010002392
    Abstract: Use of cartilage oligomeric matrix protein (COMP) or fragments or analoges thereof for the manufacture of a pharmaceutical composition for prevention or treatment of arthritic conditions is described, wherein the pharmaceutical composition is administrated in an amount effective to prevent or treat the arthritic condition.
    Type: Application
    Filed: December 28, 2000
    Publication date: May 31, 2001
    Applicant: Astra Aktiebolag
    Inventors: Dick Heinegard, Lars Klareskog, Johnny C. Lorentzen
  • Antiparathyroid antibodies which specifically bind to cell surface molecules on parathyroid, renal and cytotrophoblast cells which are involved in calcium sensing
    Patent number: 5476921
    Abstract: Antibody preparations are useful in the prognosis of parathyroid and renal disorders. The antibody preparation includes antibodies which bind specifically to a surface antigen, Ca.sup.2+ sensing structure, present in humans on the parathyroid, on the proximal tubuli of the kidney, on the cytotrophoblastic cells of the placenta, on renal carcinoma cells and on parathyroid cancer cells.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: December 19, 1995
    Inventors: Claes Juhlin, Rikard Holmdahl, Lars Klareskog, Jonas Rastad, Goran Akerstrom